Molecure reports first-half loss and Molecure stock gains 3.18 percent

Published on 10/01/2026 at 22:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Operating loss fell 30.56 percent to PLN 6.34 million in first-half 2026. Molecure stock costs EUR 1.62 on October 1, 2026 after EUR 1.57.

Molecure, PLONCTH00011, Illustration mit AI erstellt.

Molecure (ISIN PLONCTH00011) reported a PLN 6.34 million operating loss for the first half of 2026, while Molecure stock was trading at EUR 1.62 at Lang & Schwarz on October 1, 2026 at 10:44 p.m. CEST, up 3.18 percent versus the prior close of EUR 1.57. The half-year report dated September 30, 2026 gives investors a fresh view of the company's cash use and development pipeline.

Operating loss narrows in 2026

According to Parkiet on September 30, 2026, Molecure's operating loss narrowed to PLN 6.34 million in the first half of 2026 from PLN 9.13 million in the first half of 2025, a 30.56 percent improvement in the loss.

The result came with lower operating revenue. Revenue declined 47.08 percent year over year to PLN 1.86 million from PLN 3.52 million, while net loss per share improved to PLN 0.29 from PLN 0.41 in the same periods.

Cash use remains central

Net cash from operating activities was negative PLN 1.39 million in the first half of 2026, compared with negative PLN 10.64 million in the first half of 2025. The comparison points to lower operating cash consumption, although Molecure remains dependent on financing and successful development milestones because its business is built around clinical-stage drug candidates.

The company describes OATD-01 as its most advanced proprietary candidate, targeting interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis. OATD-02 is in Phase I development for cancer, according to Molecure. The company says it began a Phase II sarcoidosis trial for OATD-01 in March 2024, making clinical progress more important to valuation than current revenue.

October report date is set

Molecure's investor calendar lists October 30, 2026 for publication of its third-quarter 2026 report. The next report will give the market another dated checkpoint on research spending, financing capacity and progress across the pipeline.

Stock gains after report date

Molecure stock was trading at EUR 1.62 at Lang & Schwarz on October 1, 2026 at 10:44 p.m. CEST, an increase of 3.18 percent against the prior close of EUR 1.57. The primary WSE quote was PLN 7.14 on October 1, 2026 at 3:00 p.m. UTC, with a market capitalization of PLN 176.5 million and a 52-week range of PLN 4.98 to PLN 9.04.